drugset / Trial / NCT00459173

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

NCT00459173

Phase 3 Completed 4850 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month treatment period and to evaluate the pharmacokinetics of the drug.

Timeline

Start
2002-11
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimonabant Small molecule 5 mg
Subject Rimonabant Small molecule 20 mg

Indications

No indication recorded.